TAP EN Article Feed https://ascopost.com/ All the latest and greatest ASCO Post articles and news. Fri, 01 May 2026 05:30:32 +00:00 en-US hourly 1 FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, <em>ESR1</em>-Mutated Advanced Breast Cancer https://ascopost.com/news/may-2026/fda-approves-vepdegestrant-for-er-her2-esr1-advanced-breast-cancer/ Fri, 01 May 2026 05:30:32 +00:00 The ASCO Post The heterobifunctional protein degrader was approved for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

]]> What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate https://ascopost.com/issues/april-25-2026/what-is-the-optimal-setting-for-t-dxd-in-early-breast-cancer/ Fri, 01 May 2026 03:40:42 +00:00 The ASCO Post Trastuzumab deruxtecan (T-DXd) is reshaping the treatment landscape for HER2-positive and some HER2-low breast cancers. At the 43rd Annual Miami Breast Cancer Conference, investigators debated whether this antibody-drug conjugate is most effective in the neoadjuvant or adjuvant setting.

]]>